Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4727-4736

  Liu, Ping ^a   Mould, Diane R ^b  

^a PFIZER INC   (United States)

^b Projections Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ASPERGILLOSIS; ASPERGILLUS; BIOAVAILABILITY; BLOOD; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; FEMALE; HALF LIFE TIME; HALLUCINATIONS; HUMAN; MALE; MICROBIOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PHOTOPHOBIA; PHYSIOLOGY; PROSPECTIVE STUDY; STATISTICAL MODEL; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; AREA UNDER CURVE; ASPERGILLOSIS; ASPERGILLUS; BIOLOGICAL AVAILABILITY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG-INDUCED LIVER INJURY; ECHINOCANDINS; FEMALE; HALF-LIFE; HALLUCINATIONS; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PHOTOPHOBIA; PROSPECTIVE STUDIES; VORICONAZOLE;

EID: 84905407748     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02809-13     Document Type: Article

References (23)

1. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. 2006. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J. Clin. Pharmacol. 46:235-243. http://dx.doi.org/10.1177/0091270005283837.
2. Pfizer. 2010. VFEND® (voriconazole) United States package insert. Pfizer Inc., New York, NY.
3. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211. http://dx.doi.org/10.1086/524669.
4. Ueda K, Nannya Y, Kumano K, Hangaishi A, Takahashi T, Imai Y, Kurokawa M. 2009. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int. J. Hematol. 89:592-599. http://dx.doi.org/10.1007/ s12185-009-0296-3.
5. Miyakis S, van Hal SJ, Ray J, Marriott D. 2010. Voriconazole concentrations and outcome of invasive fungal infections. Clin. Microbiol. Infect. 16:927-933. http://dx.doi.org/10.1111/j.1469-0691.2009.02990.x.
6. Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. 2010. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin. Infect. Dis. 50:27-36. http://dx.doi.org/10.1086/648679.
7. Troke PF, Hockey HP, Hope WW. 2011. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob. Agents Chemother. 55:4782-4788. http://dx.doi.org/10.1128/ AAC.01083-10.
8. Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH, Song KH, Choe PG, Kim NJ, Jang IJ, Oh MD, Yu KS. 2012. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin. Infect. Dis. 55:1080-1087. http://dx.doi.org/10.1093/ cid/cis599.
9. Dolton MJ, Ray JE, Chen SC, Ng K, Pont LG, McLachlan AJ. 2012. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob. Agents Chemother. 56:4793-4799. http://dx.doi.org/10. 1128/AAC.00626-12.
10. Mitsani D, Nguyen MH, Shields RK, Toyoda Y, Kwak EJ, Silveira FP, Pilewski JM, Crespo MM, Bermudez C, Bhama JK, Clancy CJ. 2012. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob. Agents Chemother. 56:2371-2377. http://dx.doi.org/10.1128/AAC.05219-11.
11. Hamada Y, Seto Y, Yago K, Kuroyama M. 2012. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis. J. Infect. Chemother. 18:501-507. http://dx.doi.org/10.1007/ s10156-011-0363-6.
12. Seyedmousavi S, Mouton JW, Verweij PE, Bruggemann RJ. 2013. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Rev. Anti Infect. Ther. 11:931-941. http://dx.doi.org/10.1586/14787210. 2013.826989.
13. Bruggemann RJ, Donnelly JP, Aarnoutse RE, Warris A, Blijlevens NM, Mouton JW, Verweij PE, Burger DM. 2008. Therapeutic drug monitoring of voriconazole. Ther. Drug Monit. 30:403-411. http://dx.doi.org/10.1097/FTD.0b013e31817b1a95.
14. Chu HY, Jain R, Xie H, Pottinger P, Fredricks DN. 2013. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events. BMC Infect. Dis. 13:105. http://dx.doi.org/10.1186/1471-2334-13-105.
15. Racil Z, Winterova J, Kouba M, Zak P, Malaskova L, Buresova L, Toskova M, Lengerova M, Kocmanova I, Weinbergerova B, Timilsina S, Rolencova M, Cetkovsky P, Mayer J. 2012. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience. Mycose. 55:483-492. http://dx.doi.org/10.1111/j.1439-0507.2012.02186.x.
16. Marr KA, Schlamm HT, Rottinghaus ST, Jagannatha S, Bow EJ, Wingard JR, Pappas P, Herbrecht R, Walsh TJ, Maertens J, Mycoses Study Group. 2012. A randomised, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. Poster LB2812, 22nd Eur. Congr. Clin. Microbiol. Infect. Dis. London, United Kingdom.
17. Liu P, Mould DR. 2014. Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis. Antimicrob. Agents Chemother. 58:4718-4726. http://dx.doi.org/10.1128/AAC.02808- 13.
18. Mavridou E, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton JW. 2010. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob. Agents Chemother. 54:4758-4764. http://dx.doi.org/10.1128/AAC.00606-10.
19. Seyedmousavi S, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton JW. 2013. Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis. Antimicrob. Agents Chemother. 57:303-308. http://dx.doi.org/10.1128/AAC.01430- 12.
20. Pfizer. 2010. ERAXIS" (anidulafungin), United States package insert. Pfizer Inc., New York, NY.
21. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. 2002. Pharmacokinetics and safety of voriconazole following intravenousto oral-dose escalation regimens. Antimicrob. Agents Chemother. 46:2546-2553. http://dx.doi.org/10.1128/AAC.46.8.2546-2553.2002.
22. Baddley JW, Andes DR, Marr KA, Kontoyiannis DP, Alexander BD, Kauffman CA, Oster RA, Anaissie EJ, Walsh TJ, Schuster MG, Wingard JR, Patterson TF, Ito JI, Williams OD, Chiller T, Pappas PG. 2010. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin. Infect. Dis. 50:1559-1567. http://dx.doi.org/10.1086/652768.
23. Andes D, Pascual A, Marchetti O. 2009. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob. Agents Chemother. 53:24-34. http://dx.doi.org/10.1128/AAC.00705-08.